Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics
Authors: Handley Katelyn F. , Sims Travis T. , Bateman Nicholas W. , Glassman Deanna , Foster Katherine I. , Lee Sanghoon , Yao Jun , Yao Hui , Fellman Bryan M. , Liu Jinsong , Lu Zhen , Conrads Kelly A. , Hood Brian L. , Barakat Waleed , Zhao Li , Zhang Jianhua , Westin Shannon N. , Celestino Joseph , Rangel Kelly M. , Badal Sunil , Pereira Igor , Ram Prahlad T. , Maxwell George L. , Eberlin Livia S. , Futreal P. Andrew , Bast Robert C. , Fleming Nicole D. , Conrads Thomas P. , Sood Anil K. 
Published: October 2022

Importance

Despite similar histologic appearance among high-grade serous ovarian cancers (HGSOCs), clinical observations suggest vast differences in gross appearance. There is currently no systematic framework by which to classify HGSOCs according to their gross morphologic characteristics.

Objective

To develop and characterize a gross morphologic classification system for HGSOC.

Design, Setting, and Participants

This cohort study included patients with suspected advanced-stage ovarian cancer who presented between April 1, 2013, and August 5, 2016, to the University of Texas MD Anderson Cancer Center, a large referral center. Patients underwent laparoscopic assessment of disease burden before treatment and received a histopathologic diagnosis of HGSOC. Researchers assigning morphologic subtype and performing molecular analyses were blinded to clinical outcomes. Data analysis was performed between April 2020 and November 2021.

Exposures

Gross tumor morphologic characteristics.

Main Outcomes and Measures

Clinical outcomes and multiomic profiles of representative tumor samples of type I or type II morphologic subtypes were compared.

Results

Of 112 women (mean [SD] age 62.7 [9.7] years) included in the study, most patients (84% [94]) exhibited a predominant morphologic subtype and many (63% [71]) had a uniform morphologic subtype at all involved sites. Compared with those with uniform type I morphologic subtype, patients with uniform type II morphologic subtype were more likely to have a favorable Fagotti score (83% [19 of 23] vs 46% [22 of 48]; P = .004) and thus to be triaged to primary tumor reductive surgery. Similarly, patients with uniform type II morphologic subtype also had significantly higher mean (SD) estimated blood loss (639 [559; 95% CI, 391-887] mL vs 415 [527; 95% CI, 253-577] mL; P = .006) and longer mean (SD) operative time (408 [130; 95% CI, 350-466] minutes vs 333 [113; 95% CI, 298-367] minutes; P = .03) during tumor reductive surgery. Type I tumors had enrichment of epithelial-mesenchymal transition (false discovery rate [FDR] q-value, 3.10 × 10−24), hypoxia (FDR q-value, 1.52 × 10−5), and angiogenesis pathways (FDR q-value, 2.11 × 10−2), whereas type II tumors had enrichment of pathways related to MYC signaling (FDR q-value, 2.04 × 10−9) and cell cycle progression (FDR q-value, 1.10 × 10−5) by integrated proteomic and transcriptomic analysis. Abundances of metabolites and lipids also differed between the 2 morphologic subtypes.

Conclusions and Relevance

This study identified 2 novel, gross morphologic subtypes of HGSOC, each with unique clinical features and molecular signatures. The findings may have implications for triaging patients to surgery or chemotherapy, identifying outcomes, and developing tailored therapeutic strategies.